Repackaging of Avastin for Retinal Disease Treatment

This technical report outlines the regulatory framework and challenges associated with the repackaging of Avastin, a medication used for treating retinal diseases, following the FDA's 2018 final guidance on biological products. The report begins with a historical context of the Drug Quality and Security Act (DQSA) and its implications for compounding practices in the United States. It details the establishment of outsourcing facilities under section 503B, which are required to adhere to stringent current good manufacturing practice (cGMP) standards. The report highlights the complexities faced by outsourcing facilities in meeting these new requirements, particularly in relation to the repackaging of Avastin, which was not originally designed for ophthalmic use. It discusses the specific stability testing and quality assurance measures mandated by the FDA, including compliance with USP standards for particulate matter. The report emphasizes the importance of ensuring patient safety through adherence to these regulatory standards and the ongoing challenges in the industry.